GlassScriptPhysician profile
Tamu Brown
NPI 1609009174
$7,562.74
in general payments reported to CMS, 2019-2025
29 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $261 · 2021: $556 · 2022: $1,282 · 2023: $1,312 · 2024: $1,340 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,978 · Education: $6.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,977.54 |
| Education | $6.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $998.62 | 2019-2025 | |
| Pfizer INC. | $827.96 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $651.59 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $533.67 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $528.59 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $495.16 | 2019-2025 | Nemluvio |
| Abbvie INC. | $474.71 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $399.61 | 2019-2024 | |
| Lilly USA, LLC | $350.50 | 2019-2025 | Ebglyss, Taltz |
| Janssen Biotech, INC. | $342.03 | 2023-2025 | Tremfya |
| Organon LLC | $289.00 | 2025 | Vtama |
| Leo Pharma INC. | $287.06 | 2022-2025 | Adbry, Spevigo |
| Arcutis Biotherapeutics, INC. | $231.84 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $211.73 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $157.37 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $153.78 | 2019 | |
| Lumenis, INC | $110.53 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $100.34 | 2019-2025 | Jublia |
| Ucb, INC. | $88.97 | 2021-2025 | Bimzelx |
| Incyte Corporation | $74.97 | 2022-2025 | Opzelura |
| Almirall LLC | $62.80 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $55.25 | 2022-2025 | Nuzyra |
| Amgen INC. | $41.74 | 2022-2025 | Otezla |
| Botanix Sb INC | $22.64 | 2025 | Sofdra |
| Journey Medical Corporation | $20.87 | 2019 | |
| Vyne Pharmaceuticals INC. | $16.50 | 2020 | |
| Epi Health, LLC | $12.57 | 2022 | |
| Merz North America, INC. | $11.34 | 2021 | |
| Glenmark Therapeutics INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamu Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.